Quick Answer: Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the responsible person for a cosmetic product must report a serious adverse event associated with use in the United States to the FDA within 15 business days. The report must include a copy of the retail label. This is a post-market safety obligation—not an FDA product approval—and it needs a clear handoff between the brand, the named responsible person and the manufacturer.
What is MoCRA adverse event reporting?
MoCRA added section 605 to the Federal Food, Drug, and Cosmetic Act. It requires the responsible person to report serious adverse events for cosmetic products marketed in the United States. The FDA explains that the responsible person is the manufacturer, packer or distributor whose name appears on the label. In many private-label projects, that makes the label decision a compliance decision as well as a branding decision.
A complaint is not automatically a reportable serious adverse event. Brands should capture all complaints, triage them promptly and assess whether the facts meet the FDA definition. When in doubt, escalation to a qualified regulatory professional is prudent.
What counts as a serious adverse event?
The FDA’s definition is specific. A serious adverse event is an adverse event that results in one of the outcomes below, or requires medical or surgical intervention to prevent one of them.
| FDA serious outcome | Examples named by FDA | Operational response |
|---|---|---|
| Death, life-threatening experience or inpatient hospitalization | Hospital admission following product use | Escalate immediately; preserve the complaint record and product details. |
| Persistent or significant disability or incapacity | A continuing functional impairment | Obtain available follow-up information and assess reportability. |
| Congenital anomaly, birth defect or infection | Infection associated with cosmetic use | Escalate to the responsible person without waiting for a routine service response. |
| Significant disfigurement | Serious and persistent rash, second- or third-degree burns, significant hair loss, or persistent/significant alteration of appearance | Document the product, use conditions, timing and available evidence. |
Routine dissatisfaction, a fragrance preference or a non-serious quality complaint does not by itself prove a serious adverse event. However, a non-serious event can still matter for quality investigation, trend review, corrective action and customer care.
Who must file: brand owner, manufacturer or distributor?
The legal filing obligation attaches to the responsible person. Commercial agreements can assign who gathers facts or drafts a report, but they should not obscure who is named on the retail label and who must ensure the FDA filing occurs on time.
| Party | Typical role | Key responsibility |
|---|---|---|
| Responsible person | The manufacturer, packer or distributor named on the label | Assess reportability, submit the serious adverse event report, include the label copy and submit qualifying follow-up information. |
| Brand owner | Owns consumer communication, claims and retail presentation | Route complaints rapidly, retain traceable case records and confirm the named responsible person. |
| Cosmetic manufacturer | Holds production and technical evidence | Provide batch traceability, formula/INCI information, retained-sample status and relevant quality investigation facts when requested. |
| Importer or distributor | Receives market feedback or operates local channels | Maintain an agreed escalation route so reports do not sit in a customer-service inbox. |
For overseas manufacturing, the factory may be essential to the investigation even when it is not the U.S. label’s responsible person. A launch contract should define response times, named contacts, batch-record access and how safety information is shared.
What is the 15-business-day rule?
The FDA states that the responsible person must report a serious adverse event within 15 business days. The report must include a copy of the label on or within the retail packaging. If the responsible person receives medical or other information about the event within one year of the initial report, the new information must also be submitted within 15 business days.
- Receive and preserve: log the case, date received, product identity, lot/batch if available, use conditions and contact details.
- Triage promptly: identify whether the facts suggest a serious adverse event under the FDA definition.
- Identify the responsible person: check the retail label and confirm the accountable legal entity.
- Collect supporting facts: include the retail label copy and relevant available materials without delaying the deadline.
- Submit and retain: use the FDA reporting route appropriate to the responsible person, record the submission details and manage follow-up information.
What information should a brand and manufacturer keep ready?
FDA’s industry page describes electronic and paper submission routes for serious adverse event reports. Operationally, a brand should be able to retrieve the right information quickly rather than reconstruct it from email threads.
| Information set | Why it matters | Typical source |
|---|---|---|
| Retail label copy and product identifier | FDA requires the retail label copy with a serious adverse event report. | Brand artwork control / regulatory file |
| Lot or batch and distribution traceability | Supports a focused investigation and helps identify potentially affected inventory. | Manufacturer batch documentation and distribution records |
| Complaint chronology and available medical information | Supports the seriousness assessment and any later follow-up. | Brand customer-care or safety team |
| Formula, INCI and quality investigation records | Helps the responsible person understand the product and investigate appropriately. | Manufacturer technical and quality teams |
How should a private-label brand set up its process?
- Put one responsible person and a backup in the quality agreement.
- Train customer-service, marketplace and distributor teams to escalate potential safety cases on the day received.
- Keep a controlled copy of every retail label and a route to lot/batch records.
- Agree the factory’s response window for batch records, COA, stability information, microbiological reports and retained-sample checks.
- Separate fact collection from the legal decision on reportability; do not promise a regulatory outcome to a consumer.
- Review complaint trends so a cluster of non-serious cases is not overlooked.
Common mistakes to avoid
Assuming “FDA registered” means FDA approved the product. Serious adverse event reporting is a post-market duty and does not turn a cosmetic into an FDA-approved product. Waiting for a complete investigation before escalating. The 15-business-day clock requires an organised decision path. Leaving the factory out of the plan. The manufacturer may hold the records needed to investigate. Treating every complaint as identical. A structured triage process is more useful than either dismissing or over-classifying complaints.
What can a cosmetic manufacturer provide?
For an international OEM/ODM project, MOOYAM can support the technical-documentation side of a safety investigation with available manufacturing records, including an INCI list, COA, SDS, batch documentation, stability information, microbiological reports, quality records and packaging-compatibility information. The brand and the named responsible person should still determine the applicable U.S. legal obligations and submission approach.
Related MOOYAM compliance resources
- Cosmetic Safety Substantiation Under MoCRA
- MoCRA Facility Registration vs. Product Listing
- MoCRA Requirements for Foreign Cosmetic Manufacturers
- MOOYAM OEM/ODM Cosmetics Manufacturing
FAQ
Is every cosmetic complaint reportable to FDA under MoCRA?
No. FDA requires the responsible person to report serious adverse events. Non-serious adverse-event reports may be submitted voluntarily, while all complaints should still be evaluated and documented through the company’s quality process.
Who is the responsible person under MoCRA?
It is the manufacturer, packer or distributor whose name appears on the cosmetic product label, as described by FDA. Brands should verify this from the final retail label rather than assume that a factory or importer is automatically responsible.
Does the 15-business-day deadline apply to new information?
Yes. If the responsible person receives medical or other information about the event within one year of the initial report, FDA says the new information must be submitted within 15 business days.
What should an OEM factory provide after a serious complaint?
Depending on the case and agreement, the factory can provide available batch records, formula/INCI information, quality-investigation facts, retained-sample status, COA, SDS, stability information and packaging-compatibility information. The responsible person remains accountable for the regulatory filing decision.
Official sources
- FDA: How to Report a Cosmetic Product Related Complaint
- FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
- FDA: Updated Instructions for Serious Adverse Event Reporting
Last reviewed: September 18, 2026. Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or a qualified compliance professional before placing cosmetic products on the market.
Need a manufacturing and documentation workflow for an international beauty launch? Contact MOOYAM to discuss an OEM/ODM project, target market and the technical records your team may need.